bioengineering

News

CAR-T therapies have revolutionised the treatment of some blood cancers, but are costly as well as time- and resource-intensive.

Oncology

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.